{
    "nctId": "NCT04385563",
    "briefTitle": "A Study to Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.",
    "officialTitle": "A Phase III,Randomized,Multicenter,Double-blind Clinical Trail to Evaluate the Efficacy,Safety and Immunogenicity of the Combination of TQ-B211 Plus Docetaxel Versus Herceptin\u00ae Plus Docetaxel as First-line Treatment in Patients With HER2-positive MBC.",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 338,
    "primaryOutcomeMeasure": "Objective response rate (ORR)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Ability to give written informed consent.\n* Age\uff1a\u226518 and \u226475,female.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\uff1bLife expectancy of at least 12 weeks.\n* Histologically confirmed diagnosis as her2-positive metastatic or locally recurrent breast cancer that cannot be treated with radical surgery or radiotherapy.\n* No prior systematical chemotherapy, biotherapy or molecule-targeted therapy for metastatic breast cance.\n* Patients must have a measurable disease according to RECIST v. 1.1 28 days before randomization. (Disease in brain or bone will not be included)\n* Left ventricular ejection fraction (LVEF) \u226550 percent (%)\n* Blood routine examination should meet the following conditions: Absolute neutrophil count (ANC)\u22651.5\u00d7109/L Platelets \u2265100 x 109/L Hemoglobin \u226590 g/L hemameba\u22653.0\u00d7109/L )\n* Liver function should meet the following conditions:\n\nTotal bilirubin \u22641.5x Upper Limit of Normal(ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u22643x ULN if no liver involvement or \u22645x ULN with liver involvement.\n\n-Kidney function should meet the following conditions: Cr (creatinine) \u22641.5x ULN or Ccr (creatinine clearance rate) \u226550 mL/min.\n\n* The coagulation function should meet the following conditions: International normalized ratio\uff08INR\uff09\u22641.5\uff1bActivated partial thromboplastin time or partial thromboplastin time \u22641.5\u00d7ULN\n* Female who meet the following criteria can participate in the study:\n\nNo childbearing potential\uff1b Female with childbearing potential: negative pregnancy test within 7 days before the first administration of the investigational drug; patients are not breastfeeding; Contraception use must continue for the duration of study treatment and for at least 6 months after the last dose of study treatment.\n\nExclusion Criteria:\n\n* Not eligible for docetaxel combination therapy.\n* Endocrine therapy within 2 weeks before randomization.\n* Patients had received neoadjuvant or adjuvant therapy with herceptin 12 months before randomization.\n* Patients had received neoadjuvant/adjuvant drugs containing other anthracycline or taxol 6 months before randomization.\n* Patients had used Chinese patent medicine or Chinese herbal medicine with anti-cancer activity 2 weeks before randomization.\n* Brain metastases with symptom/untreated brain metastases/other central nervous system(CNS) metastases. Treated CNS metastases remain stable for at least 4 weeks before the study, and no evidence of cerebral edema, no sign for glucosinolates or anticonvulsants treatments.\n* Patients with a previous malignancy within the past 5 years (other than curatively treated in situ carcinoma of the cervix, non-melanoma skin cancer and superficial bladder carcinoma).\n* Hepatitis virus C(HCV) positive, HIV positive, syphilis positive, or HBsAg positive and Hepatitis virus B(HBV) DNA titer in peripheral blood is beyond the normal range.\n* Patients had received major surgical procedures (including open chest biopsy) major trauma (e.g. fracture) within 4 weeks before randomization, and there are unhealed wounds, ulcers or fractures at the time of screening or major surgery is expected during the study\n* Patients have a history of hypertensive encephalopathy or a hypertension or an uncontrolled hypertension ( systolic blood pressure \\>150mmHg or diastolic blood pressure \\>100mmHg with antihypertensive drugs)\n* Patients had a history of myocardial infarction 6 months before randomization; medical history of congestive heart failure in New York heart association classification (NYHA)\u2265 grade II,and a severe arrhythmia that cannot be controlled by drugs\uff08atrial fibrillation and paroxysmal supraventricular tachycardia are excluded\uff09;LVEF had previously declined to less than 50% during or after new trastuzumab adjuvant or adjuvant therapy.\n* Allergies to herceptin \u00ae/ TQ-B211 or the chemotherapies involved in this trial and their excipients.\n* History hypersensitivity to any study drug .\n* Patients had participated in clinical trials of other antitumor drugs 4 weeks before randomization .\n* Not eligible to join the study judged by investigators.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}